# US 2013/0253032 A1 · Use of Apoptosis-specific eIF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253032 A1
- Document ID: US20130253032A1
- Status: Published application
- Kind: A1
- Application number: 13/487,951
- Filed: 2012-06-04
- Published: 2013-09-26
- Earliest claimed: 2006-03-20
- Inventors: John E. Thompson; Charles A. Dinarello
- Web page: https://patentgrep.com/patent/US20130253032A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for down regulating pro-inflammatory cytokines in a mammal by administering siRNA against eIF-5A1 to the mammal to treat/prevent sepsis and/or hemorrhagic shock.

## Claims

### Claim 1

A method for decreasing expression of pro-inflammatory cytokines in vivo in a subject, comprising administering eIF5A1 siRNA to the subject, whereby the eIF5A1 siRNA decreases expression of pro-inflammatory cytokines in the subject.

### Claim 2 (depends on 1)

The method of claim 1 wherein the subject is a human.

### Claim 3 (depends on 1)

The method of claim 1 wherein the pro-inflammatory cytokine is selected from the group consisting of IL-1β, IL-2, IL-4, IL-5, IL-10, IFN-γ, TNF-α, IL-3, IL-6, IL-12(p40), IL-12(p70), G-CSF, KC, MIP-1α, and RANTES.

### Claim 4 (depends on 1)

The method of claim 1 wherein the pro-inflammatory cytokine is TNF-α.

### Claim 5 (depends on 1)

The method of claim 1 wherein the pro-inflammatory cytokine is IL-6.

### Claim 6 (depends on 1)

The method of claim 1 wherein the pro-inflammatory cytokine is KC.

### Claim 7 (depends on 1)

The method of claim 1 wherein the pro-inflammatory cytokine is MIP-1α.

### Claim 8 (depends on 1)

The method of claim 1 wherein said decreased expression of pro-inflammatory cytokines further provides treatment of sepsis.

### Claim 9 (depends on 1)

The method of claim 1 wherein the sense strand of the eIF5A1 siRNA comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29 and SEQ ID NO:32.

### Claim 10

A pharmaceutical composition for decreasing expression of pro-inflammatory cytokines, comprising eIF5A siRNA and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 11)

The composition of claim 11 wherein the sense strand of the siRNA comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:29 and SEQ ID NO:32.

### Claim 12

A method of preventing hemorrhagic shock in a subject comprising administering an eIF5A1 siRNA or eIFA1 antisense polynucleotide to decrease expression of IL-1β and/or TNF-α in the subject, thereby preventing hemorrhagic shock.

### Claim 13 (depends on 1)

The method of claim 1 wherein the sense strand of siRNA comprises SEQ ID NO: 30 and the antisense strand comprises SEQ ID NO: 31.
